Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2017 Nov 13;17(1):73–83. doi: 10.1158/1535-7163.MCT-17-0196

Figure 5. Chemical proteomics identifies IGF1R and ACK1 as potential targets of ceritinib in BRAF/NRAS-WT melanoma.

Figure 5

A: Workflow of the chemical proteomic experiment. B: Kinome tree of potential kinase targets of ceritinib in SK-MEL-23 melanoma cells. C: Certinib inhibits IGF1R and ACK1 in in vitro kinase assays.